Gilead Sciences (GILD) 109.36 $GILD
Bristol-Myers/Pfizer's Eliquis Encourages in VTE Analysis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 5:50PM CDT
Encouraging results on Bristol-Myers /Pfizer's (BMY/PFE) Eliquis was presented from an analysis of a phase III study.
AstraZeneca Reports Data on Brilinta from ATLANTIC Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 5:40PM CDT
AstraZeneca (AZN) announced data from the phase IV ATLANTIC study on Brilinta.
Bayer/Johnson & Johnson to Expand Xarelto Label Further - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 5:30PM CDT
Bayer (BAYRY) and Johnson & Johnson (JNJ) announced that they will be evaluating Xarelto in three new indications.
United Therapeutics Soars on Remodulin Patent Case Win - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 5:25PM CDT
The U.S. District Court for the District of New Jersey has rendered a favorable decision in the Remodulin patent infringement lawsuit against Sandoz.
Final Glance: Biotechnology companies
AP - Tue Sep 02, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Novartis Releases Positive Data on LCZ696 for Heart Failure - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 4:10PM CDT
Novartis (NVS) announced positive data on its pipeline candidate, LCZ696 from its PARADIGM-HF study. The data was published in the New England Journal of Medicine.
After Yesterday's Rally of 1.67% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Sep 02, 3:38PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $107.61 to a high of $109.50. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $108.77 on volume of 15.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Watch for Gilead Sciences to Potentially Pullback After Gaining 1.67% Yesterday
Comtex SmarTrend(R) - Tue Sep 02, 3:38PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $107.61 to a high of $109.50. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $108.77 on volume of 15.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Prestige Brands to Sell Bonine for Insight Acquisition - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 3:35PM CDT
Prestige Brands Holdings, Inc., (PBH) announced that it has agreed to divest assets and marketing rights for OTC motion sickness drug Bonine as per the instructions of the Federal Trade Commission.
BioCryst's Ebola Candidate Moving to Efficacy Study Soon - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 2:08PM CDT
BioCryst 's (BCRX) BCX4430 will be evaluated in a non-human primate study shortly.
Midday Glance: Biotechnology companies
AP - Tue Sep 02, 12:22PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Cramer: What's Working, What's Not
at The Street - Tue Sep 02, 11:05AM CDT
Yep, the bets for the rest of 2014 are being placed.
Gilead Sciences (GILD) Breaks Through Resistance at $108.27
Comtex SmarTrend(R) - Tue Sep 02, 10:14AM CDT
Gilead Sciences (NASDAQ:GILD) has opened bullishly above the pivot of $107.53 today and has reached the first level of resistance at $108.27. Investors may be interested in a cross of the next upside pivot targets of $108.99 and $110.45.
Early Glance: Biotechnology companies
AP - Tue Sep 02, 9:57AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
48.9% Return Seen to Date on SmarTrend Gilead Sciences Call (GILD)
Comtex SmarTrend(R) - Tue Sep 02, 9:12AM CDT
SmarTrend identified an Uptrend for Gilead Sciences (NASDAQ:GILD) on April 22nd, 2014 at $72.56. In approximately 4 months, Gilead Sciences has returned 48.88% as of today's recent price of $108.02.
Ambit Biosciences (AMBI) Jumps: Stock Up 6.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 8:04AM CDT
Ambit Biosciences Corporation (AMBI) was a big mover last session, as the company saw its shares rise over 6% on the day.
3 Simple Ways to Invest Like George Soros
George Budwell, The Motley Fool - Motley Fool - Sat Aug 30, 10:42AM CDT
Source: Wikimedia commons Before investing a single penny, you should have some type of overarching strategy or philosophy as a guide. Most commonly, the average investor turns to Warren Buffett in the hope of cracking Wall Street's secret code....
Regeneron Pharmaceuticals' Pipeline Progress Raises Costs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 29, 5:30PM CDT
Regeneron (REGN) expects adjusted SG&A costs to rise further in the remaining quarters of 2014.
Pfizer's C. Difficile Vaccine Gets Fast Track Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 29, 5:10PM CDT
Pfizer Inc. (PFE) announced that its vaccine candidate for clostridium difficile infection has been granted fast track designation by the FDA.
Bristol-Myers/Pfizer's Eliquis Encourages in VTE Analysis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 5:50PM CDT
Encouraging results on Bristol-Myers /Pfizer's (BMY/PFE) Eliquis was presented from an analysis of a phase III study.
AstraZeneca Reports Data on Brilinta from ATLANTIC Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 5:40PM CDT
AstraZeneca (AZN) announced data from the phase IV ATLANTIC study on Brilinta.
Bayer/Johnson & Johnson to Expand Xarelto Label Further - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 5:30PM CDT
Bayer (BAYRY) and Johnson & Johnson (JNJ) announced that they will be evaluating Xarelto in three new indications.
United Therapeutics Soars on Remodulin Patent Case Win - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 5:25PM CDT
The U.S. District Court for the District of New Jersey has rendered a favorable decision in the Remodulin patent infringement lawsuit against Sandoz.
Final Glance: Biotechnology companies
AP - Tue Sep 02, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Novartis Releases Positive Data on LCZ696 for Heart Failure - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 4:10PM CDT
Novartis (NVS) announced positive data on its pipeline candidate, LCZ696 from its PARADIGM-HF study. The data was published in the New England Journal of Medicine.
After Yesterday's Rally of 1.67% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Tue Sep 02, 3:38PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $107.61 to a high of $109.50. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $108.77 on volume of 15.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Watch for Gilead Sciences to Potentially Pullback After Gaining 1.67% Yesterday
Comtex SmarTrend(R) - Tue Sep 02, 3:38PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $107.61 to a high of $109.50. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $108.77 on volume of 15.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Prestige Brands to Sell Bonine for Insight Acquisition - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 3:35PM CDT
Prestige Brands Holdings, Inc., (PBH) announced that it has agreed to divest assets and marketing rights for OTC motion sickness drug Bonine as per the instructions of the Federal Trade Commission.
BioCryst's Ebola Candidate Moving to Efficacy Study Soon - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 2:08PM CDT
BioCryst 's (BCRX) BCX4430 will be evaluated in a non-human primate study shortly.
Midday Glance: Biotechnology companies
AP - Tue Sep 02, 12:22PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Cramer: What's Working, What's Not
at The Street - Tue Sep 02, 11:05AM CDT
Yep, the bets for the rest of 2014 are being placed.
Gilead Sciences (GILD) Breaks Through Resistance at $108.27
Comtex SmarTrend(R) - Tue Sep 02, 10:14AM CDT
Gilead Sciences (NASDAQ:GILD) has opened bullishly above the pivot of $107.53 today and has reached the first level of resistance at $108.27. Investors may be interested in a cross of the next upside pivot targets of $108.99 and $110.45.
Early Glance: Biotechnology companies
AP - Tue Sep 02, 9:57AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
48.9% Return Seen to Date on SmarTrend Gilead Sciences Call (GILD)
Comtex SmarTrend(R) - Tue Sep 02, 9:12AM CDT
SmarTrend identified an Uptrend for Gilead Sciences (NASDAQ:GILD) on April 22nd, 2014 at $72.56. In approximately 4 months, Gilead Sciences has returned 48.88% as of today's recent price of $108.02.
Ambit Biosciences (AMBI) Jumps: Stock Up 6.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 02, 8:04AM CDT
Ambit Biosciences Corporation (AMBI) was a big mover last session, as the company saw its shares rise over 6% on the day.
3 Simple Ways to Invest Like George Soros
George Budwell, The Motley Fool - Motley Fool - Sat Aug 30, 10:42AM CDT
Source: Wikimedia commons Before investing a single penny, you should have some type of overarching strategy or philosophy as a guide. Most commonly, the average investor turns to Warren Buffett in the hope of cracking Wall Street's secret code....
Regeneron Pharmaceuticals' Pipeline Progress Raises Costs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 29, 5:30PM CDT
Regeneron (REGN) expects adjusted SG&A costs to rise further in the remaining quarters of 2014.
Pfizer's C. Difficile Vaccine Gets Fast Track Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 29, 5:10PM CDT
Pfizer Inc. (PFE) announced that its vaccine candidate for clostridium difficile infection has been granted fast track designation by the FDA.
